The ClonoSEQ assay received expanded FDA clearance to detect and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
